• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PAB 0.00% 0.9¢

PATRYS LIMITED - Corporate Spotlight

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

No Corporate Spotlight currently available.

(20min delay)
Last
0.9¢
Change
0.000(0.00%)
Mkt cap ! $18.51M
Open High Low Value Volume
0.9¢ 0.9¢ 0.9¢ $900 100K

Buyers (Bids)

No. Vol. Price($)
14 2381375 0.8¢
 

Sellers (Offers)

Price($) Vol. No.
0.9¢ 720000 1
View Market Depth
Last trade - 13.21pm 19/04/2024 (20 minute delay) ?
Last
0.9¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
0.9¢ 0.9¢ 0.9¢ 511111
Last updated 15.51pm 19/04/2024 ?
PAB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.